Amgen, Inc. (AMGN) Stake Decreased by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. cut its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 77.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,622 shares of the medical research company’s stock after selling 91,843 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Amgen were worth $4,585,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Financial Advisory Service Inc. lifted its stake in Amgen by 0.3% in the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 5 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its stake in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC lifted its stake in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock valued at $190,000 after purchasing an additional 7 shares during the last quarter. Ballentine Partners LLC raised its holdings in Amgen by 0.3% during the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after acquiring an additional 9 shares during the period. Finally, Hudock Capital Group LLC raised its holdings in Amgen by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after acquiring an additional 10 shares during the period. 78.46% of the stock is owned by hedge funds and other institutional investors.

Shares of Amgen, Inc. (AMGN) traded down $1.35 during trading on Friday, reaching $173.90. 1,946,443 shares of the company’s stock were exchanged, compared to its average volume of 2,641,276. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. Amgen, Inc. has a twelve month low of $145.62 and a twelve month high of $191.10. The firm has a market cap of $127,215.83, a price-to-earnings ratio of 15.74, a price-to-earnings-growth ratio of 2.54 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. Amgen’s revenue for the quarter was down .7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.02 EPS. equities research analysts anticipate that Amgen, Inc. will post 12.67 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.04%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio is presently 41.63%.

Amgen declared that its board has initiated a stock buyback plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Several research analysts have recently weighed in on AMGN shares. BMO Capital Markets restated a “market perform” rating and set a $198.00 price target on shares of Amgen in a research report on Thursday, October 26th. Oppenheimer reiterated a “buy” rating and set a $203.00 target price on shares of Amgen in a report on Thursday, September 7th. Mizuho reissued a “buy” rating and issued a $198.00 price target (up from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Finally, BidaskClub raised shares of Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $189.94.

In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the sale, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders sold 8,575 shares of company stock worth $1,509,339 in the last quarter. Company insiders own 0.19% of the company’s stock.

WARNING: This story was published by Week Herald and is owned by of Week Herald. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://weekherald.com/2017/12/30/amgen-inc-amgn-position-lessened-by-edmond-de-rothschild-holding-s-a.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply